Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas: Possible involvement of alpha-2A adrenergic receptor subtype

Hiroshi Hirose, H. Maruyama, K. Itoh, K. Koyama, K. Kido, T. Saruta

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Although insulin release is known to be inhibited by alpha-2 adrenergic agonism, the effect of alpha adrenergic agonism on islet glucagon release remains controversial. Alpha-2 adrenoceptors are subdivided into alpha-2A and alpha-2B subtypes using receptor binding methods or cloning methodology. This study was designed to confirm the involvement of the alpha-2 adrenoceptor and its subtypes in glucagon release from the isolated, perfused rat pancreas. Both the alpha-2A preferential agonist oxymetazoline and the non-subtype-selective alpha-2 agonist clonidine induced concentration-dependent stimulation of glucagon release, starting at 10-8 and 10-7 mol/l, respectively (p < 0.01). In contrast, neither of the two alpha-1 selective agonists, methoxamine and phenylephrine, at concentrations up to 10-6 mol/l affected glucagon release. Furthermore, the non-subtype-selective alpha-2 antagonist rauwolscine at concentrations of 10-6 and 10-5 mol/l and the alpha-1 and alpha-2A selective antagonist WB-4101 at 10-5 mol/l showed significant antagonism of 10-7 mol/l clonidine-induced glucagon release versus corresponding controls. Neither the alpha-1 and alpha-2B selective antagonist prazosin nor the alpha-2B preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/l, antagonized the effects of clonidine. None of the eight drugs, at the concentrations tested, affected insulin release with 5.5 mmol/l glucose. These results suggest that in rats islet glucagon release induced by alpha adrenoceptor agonism is mediated through alpha-2 adrenoceptors, possibly the alpha-2A subtype.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalActa Endocrinologica
Volume127
Issue number3
Publication statusPublished - 1992

Fingerprint

Adrenergic alpha-2 Receptors
Glucagon
Adrenergic Agents
Pancreas
Adrenergic Receptors
Clonidine
Oxymetazoline
Insulin
Methoxamine
Yohimbine
Prazosin
Chlorpromazine
Phenylephrine
Organism Cloning
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology

Cite this

Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas : Possible involvement of alpha-2A adrenergic receptor subtype. / Hirose, Hiroshi; Maruyama, H.; Itoh, K.; Koyama, K.; Kido, K.; Saruta, T.

In: Acta Endocrinologica, Vol. 127, No. 3, 1992, p. 279-283.

Research output: Contribution to journalArticle

@article{aa5784d1d63f40d09d0c5358cdb1e9c4,
title = "Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas: Possible involvement of alpha-2A adrenergic receptor subtype",
abstract = "Although insulin release is known to be inhibited by alpha-2 adrenergic agonism, the effect of alpha adrenergic agonism on islet glucagon release remains controversial. Alpha-2 adrenoceptors are subdivided into alpha-2A and alpha-2B subtypes using receptor binding methods or cloning methodology. This study was designed to confirm the involvement of the alpha-2 adrenoceptor and its subtypes in glucagon release from the isolated, perfused rat pancreas. Both the alpha-2A preferential agonist oxymetazoline and the non-subtype-selective alpha-2 agonist clonidine induced concentration-dependent stimulation of glucagon release, starting at 10-8 and 10-7 mol/l, respectively (p < 0.01). In contrast, neither of the two alpha-1 selective agonists, methoxamine and phenylephrine, at concentrations up to 10-6 mol/l affected glucagon release. Furthermore, the non-subtype-selective alpha-2 antagonist rauwolscine at concentrations of 10-6 and 10-5 mol/l and the alpha-1 and alpha-2A selective antagonist WB-4101 at 10-5 mol/l showed significant antagonism of 10-7 mol/l clonidine-induced glucagon release versus corresponding controls. Neither the alpha-1 and alpha-2B selective antagonist prazosin nor the alpha-2B preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/l, antagonized the effects of clonidine. None of the eight drugs, at the concentrations tested, affected insulin release with 5.5 mmol/l glucose. These results suggest that in rats islet glucagon release induced by alpha adrenoceptor agonism is mediated through alpha-2 adrenoceptors, possibly the alpha-2A subtype.",
author = "Hiroshi Hirose and H. Maruyama and K. Itoh and K. Koyama and K. Kido and T. Saruta",
year = "1992",
language = "English",
volume = "127",
pages = "279--283",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas

T2 - Possible involvement of alpha-2A adrenergic receptor subtype

AU - Hirose, Hiroshi

AU - Maruyama, H.

AU - Itoh, K.

AU - Koyama, K.

AU - Kido, K.

AU - Saruta, T.

PY - 1992

Y1 - 1992

N2 - Although insulin release is known to be inhibited by alpha-2 adrenergic agonism, the effect of alpha adrenergic agonism on islet glucagon release remains controversial. Alpha-2 adrenoceptors are subdivided into alpha-2A and alpha-2B subtypes using receptor binding methods or cloning methodology. This study was designed to confirm the involvement of the alpha-2 adrenoceptor and its subtypes in glucagon release from the isolated, perfused rat pancreas. Both the alpha-2A preferential agonist oxymetazoline and the non-subtype-selective alpha-2 agonist clonidine induced concentration-dependent stimulation of glucagon release, starting at 10-8 and 10-7 mol/l, respectively (p < 0.01). In contrast, neither of the two alpha-1 selective agonists, methoxamine and phenylephrine, at concentrations up to 10-6 mol/l affected glucagon release. Furthermore, the non-subtype-selective alpha-2 antagonist rauwolscine at concentrations of 10-6 and 10-5 mol/l and the alpha-1 and alpha-2A selective antagonist WB-4101 at 10-5 mol/l showed significant antagonism of 10-7 mol/l clonidine-induced glucagon release versus corresponding controls. Neither the alpha-1 and alpha-2B selective antagonist prazosin nor the alpha-2B preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/l, antagonized the effects of clonidine. None of the eight drugs, at the concentrations tested, affected insulin release with 5.5 mmol/l glucose. These results suggest that in rats islet glucagon release induced by alpha adrenoceptor agonism is mediated through alpha-2 adrenoceptors, possibly the alpha-2A subtype.

AB - Although insulin release is known to be inhibited by alpha-2 adrenergic agonism, the effect of alpha adrenergic agonism on islet glucagon release remains controversial. Alpha-2 adrenoceptors are subdivided into alpha-2A and alpha-2B subtypes using receptor binding methods or cloning methodology. This study was designed to confirm the involvement of the alpha-2 adrenoceptor and its subtypes in glucagon release from the isolated, perfused rat pancreas. Both the alpha-2A preferential agonist oxymetazoline and the non-subtype-selective alpha-2 agonist clonidine induced concentration-dependent stimulation of glucagon release, starting at 10-8 and 10-7 mol/l, respectively (p < 0.01). In contrast, neither of the two alpha-1 selective agonists, methoxamine and phenylephrine, at concentrations up to 10-6 mol/l affected glucagon release. Furthermore, the non-subtype-selective alpha-2 antagonist rauwolscine at concentrations of 10-6 and 10-5 mol/l and the alpha-1 and alpha-2A selective antagonist WB-4101 at 10-5 mol/l showed significant antagonism of 10-7 mol/l clonidine-induced glucagon release versus corresponding controls. Neither the alpha-1 and alpha-2B selective antagonist prazosin nor the alpha-2B preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/l, antagonized the effects of clonidine. None of the eight drugs, at the concentrations tested, affected insulin release with 5.5 mmol/l glucose. These results suggest that in rats islet glucagon release induced by alpha adrenoceptor agonism is mediated through alpha-2 adrenoceptors, possibly the alpha-2A subtype.

UR - http://www.scopus.com/inward/record.url?scp=0026673641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026673641&partnerID=8YFLogxK

M3 - Article

C2 - 1357904

AN - SCOPUS:0026673641

VL - 127

SP - 279

EP - 283

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -